Skip to content
10-K

Annual Report

BridgeBio Pharma, Inc. BBIO

0001743881-26-000009

← back to feed
Filed
Feb 24, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 12, 2026 193.86M sh
Shares Diluted FY 2025 · Dec 31, 2025 191.53M sh
Shares Diluted FY 2025 · Dec 31, 2024 186.08M sh
Shares Diluted FY 2025 · Dec 31, 2023 162.79M sh
Stock Repurchased FY 2025 · Dec 31, 2025 $48.28M
Stock Repurchased FY 2025 · Dec 31, 2024 $0
Stock Repurchased FY 2025 · Dec 31, 2023 $0
Capex FY 2025 · Dec 31, 2025 $1.1M
Capex FY 2025 · Dec 31, 2024 $933K
Capex FY 2025 · Dec 31, 2023 $1.31M
Operating Cash Flow FY 2025 · Dec 31, 2025 −$445.91M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$520.73M
Operating Cash Flow FY 2025 · Dec 31, 2023 −$527.72M
Cash And Equivalents FY 2025 · Dec 31, 2025 $570.12M
Cash And Equivalents FY 2025 · Dec 31, 2024 $681.1M
Cash And Equivalents FY 2025 · Dec 31, 2023 $375.94M
Stockholders Equity FY 2025 · Dec 31, 2025 −$2.09B
Stockholders Equity FY 2025 · Dec 31, 2024 −$1.47B
Current Liabilities FY 2025 · Dec 31, 2025 $287.97M
Current Liabilities FY 2025 · Dec 31, 2024 $154.4M
Total Liabilities FY 2025 · Dec 31, 2025 $3.01B
Total Liabilities FY 2025 · Dec 31, 2024 $2.38B
Current Assets FY 2025 · Dec 31, 2025 $797.75M
Current Assets FY 2025 · Dec 31, 2024 $720.69M
Total Assets FY 2025 · Dec 31, 2025 $936.03M
Total Assets FY 2025 · Dec 31, 2024 $919.34M
Eps Diluted FY 2025 · Dec 31, 2025 −$3.78
Eps Diluted FY 2025 · Dec 31, 2024 −$2.88
Eps Diluted FY 2025 · Dec 31, 2023 −$3.95
Eps Basic FY 2025 · Dec 31, 2025 −$3.78
Eps Basic FY 2025 · Dec 31, 2024 −$2.88
Eps Basic FY 2025 · Dec 31, 2023 −$3.95
Sga Expense FY 2025 · Dec 31, 2025 $531.23M
Sga Expense FY 2025 · Dec 31, 2024 $288.93M
Sga Expense FY 2025 · Dec 31, 2023 $150.59M
Rd Expense FY 2025 · Dec 31, 2025 $451.95M
Rd Expense FY 2025 · Dec 31, 2024 $506.46M
Rd Expense FY 2025 · Dec 31, 2023 $455.71M
Operating Income FY 2025 · Dec 31, 2025 −$523.41M
Operating Income FY 2025 · Dec 31, 2024 −$592.97M
Operating Income FY 2025 · Dec 31, 2023 −$607.37M
Cost Of Revenue FY 2025 · Dec 31, 2025 $20.96M
Cost Of Revenue FY 2025 · Dec 31, 2024 $3.88M
Cost Of Revenue FY 2025 · Dec 31, 2023 $2.45M
Revenue FY 2025 · Dec 31, 2025 $502.08M
Revenue FY 2025 · Dec 31, 2024 $221.9M
Revenue FY 2025 · Dec 31, 2023 $9.3M